Literature DB >> 19330306

Advances in management of thalassemia.

M B Agarwal1.   

Abstract

Thalassemias represent the most common single-gene disorder causing a major public health problem in India. Thalassemia and hemoglobinopathies probably developed over 7000 years ago as a defense against malaria. In simple terms, thalassemia is caused by a mutation in either the â-globin chain or the á-globin chain which combine equally in red cells to form hemoglobin. These mutations lead to varying degree of anemia resulting into thalassemia minor, intermedia or major. Present write up relates to advances in the management of â-thalassemia major.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330306     DOI: 10.1007/s12098-009-0048-7

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  13 in total

1.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.

Authors:  L J Anderson; S Holden; B Davis; E Prescott; C C Charrier; N H Bunce; D N Firmin; B Wonke; J Porter; J M Walker; D J Pennell
Journal:  Eur Heart J       Date:  2001-12       Impact factor: 29.983

2.  Arterial stiffness and endothelial function in patients with beta-thalassemia major.

Authors:  Y F Cheung; Godfrey C F Chan; S Y Ha
Journal:  Circulation       Date:  2002-11-12       Impact factor: 29.690

3.  Early detection of left ventricular dysfunction in patients with beta thalassaemia major by dobutamine stress echocardiography.

Authors:  L Hui; M P Leung; S Y Ha; A K T Chau; Y F Cheung
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

4.  Treatment of cardiac iron overload in thalassemia major.

Authors:  Mark Westwood; Lisa J Anderson; Dudley J Pennell
Journal:  Haematologica       Date:  2003-05       Impact factor: 9.941

5.  Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.

Authors:  Roland Fischer; Filomena Longo; Peter Nielsen; Rainer Engelhardt; Robert C Hider; Antonio Piga
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

6.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool.

Authors:  Peter D Jensen; Finn T Jensen; Thorkil Christensen; Hans Eiskjaer; Ulrik Baandrup; Johan L Nielsen
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

Review 7.  Evaluation of iron overload.

Authors:  Peter-D Jensen
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

8.  Complications of beta-thalassemia major in North America.

Authors:  Melody J Cunningham; Eric A Macklin; Ellis J Neufeld; Alan R Cohen
Journal:  Blood       Date:  2004-02-26       Impact factor: 22.113

9.  Bone Marrow Transplantation in Thalassemia.

Authors:  B Erer; G Lucarelli
Journal:  Turk J Haematol       Date:  1999-12-05       Impact factor: 1.831

Review 10.  Growth and puberty and its management in thalassaemia.

Authors:  V De Sanctis
Journal:  Horm Res       Date:  2002
View more
  7 in total

1.  Thyroid function in major thalassemia patients: Is it related to height and chelation therapy?

Authors:  Peiman Eshragi; Ahmad Tamaddoni; Khadijeh Zarifi; Amir Mohammadhasani; Majid Aminzadeh
Journal:  Caspian J Intern Med       Date:  2011

2.  Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010.

Authors:  D Baronciani; E Angelucci; U Potschger; J Gaziev; A Yesilipek; M Zecca; M G Orofino; C Giardini; A Al-Ahmari; S Marktel; J de la Fuente; A Ghavamzadeh; A A Hussein; C Targhetta; F Pilo; F Locatelli; G Dini; P Bader; C Peters
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

3.  Evaluation of growth, puberty and endocrine dysfunctions in relation to iron overload in multi transfused Indian thalassemia patients.

Authors:  Rashid H Merchant; Amruta Shirodkar; Javed Ahmed
Journal:  Indian J Pediatr       Date:  2011-01-14       Impact factor: 1.967

4.  Iron overload in Beta thalassaemia major and intermedia patients.

Authors:  Amit Kumar Mishra; Archana Tiwari
Journal:  Maedica (Buchar)       Date:  2013-09

Review 5.  Past, present & future scenario of thalassaemic care & control in India.

Authors:  Ishwar C Verma; Renu Saxena; Sudha Kohli
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

6.  Thalassemia Major in Adults: Short Stature, Hyperpigmentation, Inadequate Chelation, and Transfusion-Transmitted Infections are Key Features.

Authors:  Anupam Prakash; Ramesh Aggarwal
Journal:  N Am J Med Sci       Date:  2012-03

7.  Clinical and Biochemical Data of Adult Thalassemia Major patients (TM) with Multiple Endocrine Complications (MEC) versus TM Patients with Normal Endocrine Functions: A long-term Retrospective Study (40 years) in a Tertiary Care Center in Italy.

Authors:  Vincenzo De Sanctis; Heba Elsedfy; Ashraf T Soliman; Ihab Zaki Elhakim; Christos Kattamis; Nada A Soliman; Rania Elalaily
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-04-12       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.